Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
Article Details
- CitationCopy to clipboard
Lech-Maranda E, Korycka A, Robak T
Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
Mini Rev Med Chem. 2009 Jun;9(7):805-12.
- PubMed ID
- 19519505 [ View in PubMed]
- Abstract
Clofarabine is a second generation of purine nucleoside analogues designed to combine the most favorable pharmacokinetic properties of fludarabine and cladribine. Clofarabine acts by inhibiting DNA polymerases and ribonucleotide reductase as well as by inducing apoptosis in cycling and non-cycling cells. Phase I/II clinical studies revealed its efficacy in hematological malignancies, and in 2004 clofarabine was approved by the United States Food and Drug Administration for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia after at least two prior chemotherapy regimens. The mechanism of action, pharmacology and clinical activity of clofarabine is the subject of this review.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Clofarabine DNA polymerase alpha catalytic subunit Protein Humans YesInhibitorDetails Clofarabine Ribonucleoside-diphosphate reductase large subunit Protein Humans YesInhibitorDetails Fludarabine DNA polymerase alpha catalytic subunit Protein Humans YesInhibitorDetails Fludarabine Ribonucleoside-diphosphate reductase large subunit Protein Humans YesInhibitorDetails